Aberrant methylation and downregulation of sall3 in human hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 18, Issue 21, 2012, Pages 2719-2726

  Yang, Xue Xi ^a   Sun, Jing Zhe ^b   Li, Fen Xia ^a   Wu, Ying Song ^a   Du, Hong Yan ^a   Zhu, Wei ^c   Li, Xiang Hong ^d   Li, Ming ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b 306 HOSPITAL OF PLA   (China)

^c GUANGZHOU CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d FIRST MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Aberrant methylation; Down regulation mrna transcription; Hepatocellular carcinoma; Sall3

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MESSENGER RNA; SALL3 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; CPG ISLAND; DOWN REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; PROMOTER REGION; PROTEIN METHYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84863112409     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i21.2719     Document Type: Article

References (31)

1. Lai EC, Lau WY. The continuing challenge of hepatic cancer in Asia. Surgeon 2005; 3: 210-215
2. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-687
3. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428
4. Zhu J. DNA methylation and hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2006; 13: 265-273
5. Tischoff I, Tannapfe A. DNA methylation in hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1741-1748
6. Garinis GA, Patrinos GP, Spanakis NE, Menounos PG. DNA hypermethylation: when tumour suppressor genes go silent. Hum Genet 2002; 111: 115-127
7. Strathdee G, Brown R. Aberrant DNA methylation in cancer: potential clinical interventions. Expert Rev Mol Med 2002; 4: 1-17
8. Strathdee G, Brown R. Epigenetic cancer therapies: DNA methyltransferase inhibitors. Expert Opin Investig Drugs 2002; 11: 747-754
9. Jürgens G. Head and tail development of the Drosophila embryo involves spalt, a novel homeotic gene. EMBO J 1988; 7: 189-196
10. Mollereau B, Dominguez M, Webel R, Colley NJ, Keung B, de Celis JF, Desplan C. Two-step process for photoreceptor formation in Drosophila. Nature 2001; 412: 911-913
11. Dostal A, Nemeckova J, Gaillyova R. The 18q deletion syndrome and analysis of the critical region for orofacial cleft at 18q22.3. J Craniomaxillofac Surg 2009; 37: 272-275
12. Parrish M, Ott T, Lance-Jones C, Schuetz G, Schwaeger-Nickolenko A, Monaghan AP. Loss of the Sall3 gene leads to palate deficiency, abnormalities in cranial nerves, and perinatal lethality. Mol Cell Biol 2004; 24: 7102-7112
13. Shikauchi Y, Saiura A, Kubo T, Niwa Y, Yamamoto J, Murase Y, Yoshikawa H. SALL3 interacts with DNMT3A and shows the ability to inhibit CpG island methylation in hepatocellular carcinoma. Mol Cell Biol 2009; 29: 1944-1958
14. Yu J, Zhu T, Wang Z, Zhang H, Qian Z, Xu H, Gao B, Wang W, Gu L, Meng J, Wang J, Feng X, Li Y, Yao X, Zhu J. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 2007; 13: 7296-7304
15. Xia W, Ni W, Fei Q, Sun J, Zhao Y, Zhang H, Gu J, He Y, Yu J. Methylation of Sall3 gene in hepatocellular carcinoma. Zhenduanxue Lilun Yu Shijian 2010; 9: 491-494
16. Ehrich M, Zoll S, Sur S, van den Boom D. A new method for accurate assessment of DNA quality after bisulfite treatment. Nucleic Acids Res 2007; 35: e29
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408
18. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010; 61: 317-328
19. Bergsland EK, Venook AP. Hepatocellular carcinoma. Curr Opin Oncol 2000; 12: 357-361
20. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225-235
21. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005; 23: 8093-8108
22. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999; 59: 793-797
23. Tessema M, Länger F, Dingemann J, Ganser A, Kreipe H, Lehmann U. Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia 2003; 17: 910-918
24. Hua D, Hu Y, Wu YY, Cheng ZH, Yu J, Du X, Huang ZH. Quantitative methylation analysis of multiple genes using methylation-sensitive restriction enzyme-based quantitative PCR for the detection of hepatocellular carcinoma. Exp Mol Pathol 2011; 91: 455-460
25. Lambert MP, Paliwal A, Vaissière T, Chemin I, Zoulim F, Tommasino M, Hainaut P, Sylla B, Scoazec JY, Tost J, Herceg Z. Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol 2011; 54: 705-715
26. Jacinto FV, Esteller M. MGMT hypermethylation: a prognostic foe, a predictive friend. DNA Repair (Amst) 2007; 6: 1155-1160
27. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009; 8: 1409-1420
28. Ganesan A, Nolan L, Crabb SJ, Packham G. Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. Curr Cancer Drug Targets 2009; 9: 963-981
29. Cortez CC, Jones PA. Chromatin, cancer and drug therapies. Mutat Res 2008; 647: 44-51
30. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 2003; 163: 1371-1378
31. Moribe T, Iizuka N, Miura T, Kimura N, Tamatsukuri S, Ishitsuka H, Hamamoto Y, Sakamoto K, Tamesa T, Oka M. Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. Int J Cancer 2009; 125: 388-397